SCHEMBL2964543

SCHEMBL2964543

COC(=O)Cc1cccc(C(=O)OC)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.68
CYP4F2 P78329 2/20 0.66
CYP4A11 Q02928 2/20 0.66
SLC7A5 Q01650 2/20 0.57
MRGPRX4 Q96LA9 2/20 0.54
RAB9A P51151 3/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
HIF1A Q16665 1/20 0.51
TSHR P16473 2/20 0.50
FOLH1 Q04609 1/20 0.50
HPGD P15428 1/20 0.50
NPC1 O15118 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
GAA P10253 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22276734 0.89 LOXL2 (0.54) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL7885872 0.87 CYP4F2 (0.61) LOXL2CYP4F2CYP4A11SLC7A5RAB9A
SCHEMBL8057216 0.86 SLC7A5 (0.57) LOXL2CYP4F2CYP4A11SLC7A5RAB9A
SCHEMBL30489978 0.86 SLC7A5 (0.57) LOXL2SLC7A5MRGPRX4RAB9ASMN1; SMN2
SCHEMBL479999 0.86 SLC7A5 (0.57) LOXL2SLC7A5MRGPRX4RAB9ASMN1; SMN2
SCHEMBL3625604 0.86 LOXL2 (0.68) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL1492405 0.86 LOXL2 (0.68) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL29346854 0.86 SLC7A5 (0.58) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL29214273 0.86 LOXL2 (0.59) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4
SCHEMBL31068535 0.86 SLC7A5 (0.58) LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113549010-B Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof 中国科学院上海药物研究所 2023-10-20 CN disclosed
US-20230303872-A1 INK, INK SET, SET OF INK AND PRE-PROCESSING FLUID, METHOD OF DISCHARGING INK, AND INK DISCHARGING DEVICE RICOH COMPANY, LTD. (JP) 2023-09-28 US disclosed
US-20230161246-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-05-25 US disclosed
US-11649365-B2 Ink, ink set, ink container, method of printing, and printing device RICOH COMPANY, LTD. (JP) 2023-05-16 US disclosed
CN-110467531-B Preparation method of 3 '-nitro-2' -hydroxybiphenyl-3-formic acid 新发药业有限公司 2022-04-19 CN disclosed
US-20220017764-A1 INK, INK SET, INK CONTAINER, METHOD OF PRINTING, AND PRINTING DEVICE RICOH COMPANY, LTD. (JP) 2022-01-20 US disclosed
CN-113549010-A Preparation and application of compound with AMPK agonistic activity and prodrug thereof 中国科学院上海药物研究所 2021-10-26 CN disclosed
US-20170066712-A1 NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-03-09 US disclosed
US-20170066712-A1 NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-03-09 US disclosed
US-20170066712-A1 NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-03-09 US disclosed
EP-1230863-A2 Porous element Filtrona Richmond, Inc. (US) 2002-08-14 EP disclosed
EP-0881889-A4 POLYETHYLENE TEREPHTHALATE SHEATH/THERMOPLASTIC POLYMER CORE BICOMPONENT FIBERS, METHOD OF MAKING SAME AND PRODUCTS FORMED THEREFROM AMERICAN FILTRONA CORP (GB) 2000-01-05 EP disclosed
EP-0881889-A1 POLYETHYLENE TEREPHTHALATE SHEATH/THERMOPLASTIC POLYMER CORE BICOMPONENT FIBERS, METHOD OF MAKING SAME AND PRODUCTS FORMED THEREFROM Filtrona International Limited (GB) 1998-12-09 EP disclosed
US-5633082-A FORM SELF-SUSTAINING THREE-DIMENSIONAL POROUS ELEMENTS USEFUL AS INK RESERVOIRS AMERICAN FILTRONA CORPORATION (US) 1997-05-27 US disclosed
US-5620641-A Polyethylene terephthalate sheath/thermoplastic polymer core bicomponent fibers, method of making same and products formed therefrom AMERICAN FILTRONA CORPORATION (US) 1997-04-15 US disclosed
US-5607766-A FILTER, WICK AMERICAN FILTRONA CORPORATION (US) 1997-03-04 US disclosed
WO-1996039054-A1 POLYETHYLENE TEREPHTHALATE SHEATH/THERMOPLASTIC POLYMER CORE BICOMPONENT FIBERS, METHOD OF MAKING SAME AND PRODUCTS FORMED THEREFROM FILTRONA INTERNATIONAL LIMITED (GB) 1996-12-12 WO disclosed
EP-0509769-B1 Heterocyclic amides having HLE inhibiting activity ZENECA LTD (GB) 1996-09-11 EP disclosed
US-5521179-A Heterocyclic amides ZENECA LIMITED (GB) 1996-05-28 US disclosed
EP-0509769-A2 Heterocyclic amides having HLE inhibiting activity ZENECA LIMITED (GB) 1992-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066712-A1 NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE HDAC7, HDAC3, HDAC8 LOXL2 3106/4885CYP4F2 3819/4885CYP4A11 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.